Tomilade Adepoju, MD
Ophthalmology · Wilmington, DENPI 1053845065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 42.4% of the total. 2025 is the largest year on record at $245, more than ten times the $20 reported in 2020. That places this record below the midpoint for ophthalmology clinicians in DE, where the typical reported total is $1,099.
Across 16 payments — averaging $32.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$220
- Genentech USA, Inc.$107
- Dompe US, Inc.$64
- Merz Pharmaceuticals, LLC$55
- Amgen$32
- Carl Zeiss Meditec Cataract Technology Inc.$20
- plus $20 from 1 others
What the payments were for
- Food & beverage$519100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 4 | $220 |
| Genentech USA, Inc. | 4 | $107 |
| Dompe US, Inc. | 2 | $64 |
| Merz Pharmaceuticals, LLC | 2 | $55 |
| Amgen | 2 | $32 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$118
How this compares
$519 in reported general payments places this provider in the 30th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $3,714 |
| Latanoprost | 129 | $1,160 |
| Prednisolone Acetate | 16 | $991 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 55 | $647 |
| Brimonidine Tartrate | 39 | $300 |
| Timolol Maleate | 15 | $156 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Wilmington
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- Richard SherryWilmington$5K
- Michael BrosmanWilmington$5K
- Brian ToussaintWilmington$2K
- Sean ConsidineWilmington$2K
- Tabassum AliWilmington$2K
- Paula KoWilmington$2K
- Harry LebowitzWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.